Premium
Potent Inhibition of HIV‐1 Entry with a Chemically Programmed Antibody Aided by an Efficient Organocatalytic Synthesis
Author(s) -
Gavrilyuk Julia,
Uehara Hisatoshi,
Otsubo Nobumasa,
Hessell Ann,
Burton Dennis R.,
Barbas Carlos F.
Publication year - 2010
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.201000432
Subject(s) - aldol reaction , aldolase a , organocatalysis , conjugate , human immunodeficiency virus (hiv) , antibody , chemistry , computer science , combinatorial chemistry , stereochemistry , computational biology , biochemistry , virology , biology , catalysis , enzyme , enantioselective synthesis , genetics , mathematical analysis , mathematics
An organocatalytic conspiracy: Organocatalysis and an organocatalytic antibody conspire to create a novel HIV‐1 entry inhibitor. A D ‐proline catalyzed aldol reaction was used to set the key stereochemistry of CCR5 inhibitor, Aplaviroc, prior to introduction as a targeting unit for chemical programming of aldolase antibody 38C2. The resulting antibody conjugate was a potent inhibitor of HIV‐1 and SIV entry.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom